Patient Square Capital
VC Fund
Menlo Park, United States
Patient Square Capital is a dedicated health care investment firm that partners with best-in-class management teams whose products, services, and technologies improve health.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 85%
Last updated:
For AI agents: llms.txt
Industries Patient Square Capital invests in
Stages Patient Square Capital invests in
Countries Patient Square Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alex Albert
|
|||
Maria Walker
|
|||
Adam Fliss
|
|||
Karr Narula
|
|||
Neel Varshney
|
|||
| See all 7 contacts → | |||
Investment Focus
Industry
- Health Care 6 (22%)
- Biotechnology 5 (19%)
- Medical 3 (11%)
- Finance 2 (7%)
- Life Science 2 (7%)
Stage
- Private Equity 4 (15%)
- Funding Round 3 (11%)
- Series B 2 (7%)
- Series C 2 (7%)
- Series A 1 (4%)
Country
- United States 8 (30%)
- United Kingdom 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alex Albert
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
|
Maria Walker
Founding Partner & Chief Financial Officer
|
Founding Partner & Chief Financial Officer | Total investments: 0 | Find email | |
|
Adam Fliss
Founding Partner and General Counsel
|
Founding Partner and General Counsel | Total investments: 0 | Find email | |
|
Karr Narula
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
|
Neel Varshney
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Osanni Bio
|
Osanni Bio is a biotechnology company developing therapies aimed at preventing and reversing blindness caused by retinal diseases. Leveraging design-thinking in drug development, Osanni focuses on novel ocular disease treatments intended to restore vision rather than just slow disease progression | $190M / Series B / Jun 23, 2026 | |
Ambros Therapeutics
|
Ambros Therapeutics is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases. | $125M / Series A / Dec 16, 2025 | |
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $320.8M / Series D / Aug 15, 2025 | |
LXE Hearing
|
LXE Hearing is a company focused on championing hearing wellness for everyone, everywhere. The company's mission is to revolutionize hearing wellness through innovation, ensuring access to affordable, life-enhancing solutions. | $100M / Private Equity / Mar 31, 2025 | |
CorroHealth
|
CorroHealth specializes in healthcare analytics and technology-driven solutions, primarily focusing on improving revenue cycle management for healthcare systems. The company utilizes advanced analytics and proprietary AI technologies to enhance financial performance in hospitals and healthcare facilities. | Private Equity / Oct 24, 2024 | |
Nuclera
|
Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers. Nuclera's eProtein DiscoveryTM system allows scientists to rapidly produce and test proteins for drug discovery. | $75M / Series C / Oct 15, 2024 | |
|
GondolaBio
|
GondolaBio researches, develops and manufactures pharmaceutical products. | $300M / Venture - Series Unknown / Aug 16, 2024 | |
Liquidia Technologies
|
Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed toimprove the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration. | $75M / Post-IPO Equity / Jan 04, 2024 | |
Apollo Therapeutics
|
Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, University College London and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). It provides committed translational funding and drug discoveryexpertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.Apollo’s unique model provides quick, independent access to the resources to grow innovations and to champion the best of British academic research to industry. Apollo’s experienced team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, crafting each bespoke project to optimise the chances of long-term success. Apollo Therapeutics aims to create the therapies of the future by partnering with the UK’s globally leading academic science base and UK based Pharma industry to have a real impact on patient treatments and outcomes. | $33.5M / Series C / Jan 02, 2024 | |
|
Apollo Therapeutics
|
Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, University College London and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). It provides committed translational funding and drug discoveryexpertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.Apollo’s unique model provides quick, independent access to the resources to grow innovations and to champion the best of British academic research to industry. Apollo’s experienced team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, crafting each bespoke project to optimise the chances of long-term success. Apollo Therapeutics aims to create the therapies of the future by partnering with the UK’s globally leading academic science base and UK based Pharma industry to have a real impact on patient treatments and outcomes. | $235.7M / Series C / Sep 06, 2023 | |
| See all 27 investments → | |||
Co-Investors
JDRF T1D Fund
5 deals together
Narya Capital
5 deals together
Alumni Ventures
4 deals together
Bluebird Ventures
4 deals together
CAM Capital
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Patient Square Capital invest in?
Patient Square Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Private Equity and Funding Round stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Patient Square Capital?
Public channels for Patient Square Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Patient Square Capital?
The team at Patient Square Capital includes Alex Albert (Founding Partner), Maria Walker (Founding Partner & Chief Financial Officer) and Adam Fliss (Founding Partner and General Counsel), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
